Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

ALN-PCS

Phase I study

Phase I study

Trial Phase I trial, reformulated ALN-PCS Aim To investigate the safety, tolerability and LDL cholesterol lowering of ALN-PCSsc (subcutaneous injection) Study design Part A (single dose): Randomised 3:1, Single blind, Placebo controlled designPart B (multi dose): Randomised 6:2, Single blind, Placebo controlled, On or off…

read more »
ALN-PCSsc data suggest 6-month dosing

ALN-PCSsc data suggest 6-month dosing

There was more news from the Phase I trial of ALN-PCSsc, an investigational RNAi therapeutic targeting PCSK9, presented at the last Latebreaker Clinical Trials session. Following initial results, presented at the European Society of Cardiology Congress, London, data reported at the American Heart Association Scientific…

read more »